Nanjing Leads Biolabs Co., Ltd. (HKG:9887)

Hong Kong flag Hong Kong · Delayed Price · Currency is HKD
61.35
+0.55 (0.90%)
Feb 13, 2026, 4:08 PM HKT
Market Cap12.09B
Revenue (ttm)n/a
Net Income-314.72M
EPS-2.04
Shares Out198.89M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume368,723
Average Volume493,082
Open60.80
Previous Close60.80
Day's Range59.50 - 62.50
52-Week Range44.72 - 83.60
Betan/a
RSI53.88
Earnings DateNov 28, 2025

About Nanjing Leads Biolabs

Nanjing Leads Biolabs Co., Ltd., a clinical-stage biotechnology company, engages in the research, development, and commercialisation of novel antibody drugs worldwide. It develops therapies in oncology, autoimmune, and other severe diseases. The company’s lead product LBL-024, a PD-L1/4-1BB bispecific antibody for extra-pulmonary neuroendocrine carcinoma, as well as LBL-034, LBL-033, and LBL-007. In addition, it develops LeadsBody platform, a portfolio of CD3 T-cell engagers that demonstrate anti-tumor efficacy and safety in preclinical/clinica... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2012
Employees 192
Stock Exchange Hong Kong Stock Exchange
Ticker Symbol 9887
Full Company Profile

Financial Performance

Financial numbers in CNY Financial Statements